Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: Clinical Trials

38 trials for Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 recruiting, 9 completed, 6 active not recruiting, 3 terminated. 23 Phase 2, 15 Phase 1, 5 Phase 3, 2 Not applicable, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 223Recruiting 10, Active not recruiting 4, Completed 3, Terminated 2, Withdrawn 2, Not yet recruiting 1, Unknown 1
Phase 115Recruiting 5, Active not recruiting 3, Completed 3, Terminated 2, Not yet recruiting 1, Withdrawn 1
Phase 35Recruiting 2, Active not recruiting 1, Completed 1, Not yet recruiting 1
Not applicable2Recruiting 2
Phase 41Completed 1

Follow Precursor B-Cell Lymphoblastic Leukemia-Lymphoma: new trials by email Literature Review of Precursor B-Cell Lymphoblastic Leukemia-Lymphoma trials Research Report on Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma
Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Phase 1RecruitingCity of Hope Medical Center162027-04-172026-11-13
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Capivasertib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
Phase 1 / Phase 2Not yet recruitingPrincess Maxima Center for Pediatric Oncology422026-10-012025-09-16
A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL
BLB101 for Injection, Blinatumomab for Injection - Precursor B-cell Acute Lymphoblastic Leukemia
Phase 3Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China2122026-08-092026-07-23
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
BEBT-908, Cyclophosphamide, Vincristine - Acute Lymphoblastic Leukemia
Phase 2RecruitingRuijin Hospital232025-12-152026-11-17
Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
Activity Tracking, Biospecimen Collection, Cognitive Assessment - Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia
Not applicableRecruitingUniversity of Washington502025-10-152026-08-19
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Dasatinib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
Phase 1 / Phase 2RecruitingPrincess Maxima Center for Pediatric Oncology262025-10-012025-09-16
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Ruxolitinib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
Phase 1 / Phase 2RecruitingPrincess Maxima Center for Pediatric Oncology262025-10-012025-09-16
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
Venetoclax, Olverembatinib, Predinisone - Precursor B-Cell Acute Lymphoblastic Leukemia
Phase 2RecruitingFirst Affiliated Hospital of Zhejiang University362024-12-012024-12-31
Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
Nanobody-Based CD19/CD22 Tandem Dual CAR-T - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Phase 1 / Phase 2RecruitingPeking University People's Hospital502024-11-142026-03-30
Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
Blinatumomab plus Reduced-dose Chemotherapy - Precursor B-Cell Acute Lymphoblastic Leukemia
Phase 2RecruitingFirst Affiliated Hospital of Zhejiang University202024-10-172024-12-19
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
Dexamethasone, Blinatumomab, Venetoclax - Precursor B-Cell Lymphoblastic Leukemia
Phase 2RecruitingFirst Affiliated Hospital of Zhejiang University202024-08-152024-08-15
CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
CAR T cell injection - B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
Not applicableRecruitingZhu Xiaofan602024-02-012024-04-09
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
Trametinib, Dexamethasone, Cyclophosphamide - Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
Phase 1 / Phase 2RecruitingPrincess Maxima Center for Pediatric Oncology262023-11-142025-09-16
HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Decitabine, Venetoclax, Navitoclax - Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
Phase 1 / Phase 2WithdrawnPrincess Maxima Center for Pediatric Oncology2023-10-012024-06-21
Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia
Cyclophosphamide, Vincristine, Dexamethasone - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Phase 2Active not recruitingAlliance for Clinical Trials in Oncology682023-06-092026-07-10
FT819 in Subjects With B-cell Malignancies
FT819, Cyclophosphamide, Fludarabine - Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
Phase 1Active not recruitingFate Therapeutics542021-07-122026-03-19
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Phase 3RecruitingChildren's Oncology Group59512019-10-312026-08-25
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
Etoposide, Doxorubicin, Vincristine - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Phase 1CompletedUniversity of Washington242019-09-242023-07-06
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Phase 3Active not recruitingNational Cancer Institute (NCI)67202019-07-032026-11-12
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients
inotuzumab ozogamicin-dose level 2, Inotuzumab ozogamicin-dose level 1 - Leukemia, Precursor b-Cell Lymphoblastic Leukemia-Lymphoma
Phase 4CompletedPfizer1022019-07-012023-11-22

Showing 20 of 38. Sign in to see all of them.

Narrower conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma (20)  ·  Burkitt Lymphoma (16)  ·  Leukemia (9)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (8)  ·  Recurrence (7)  ·  Lymphoma, B-Cell (5)  ·  Lymphoma, Large B-Cell, Diffuse (4)  ·  Leukemia, Myeloid, Acute (3)  ·  Lymphoma, Follicular (3)  ·  Down Syndrome (2)  ·  Leukemia, Biphenotypic, Acute (2)  ·  Lymphoma (2)  ·  Neoplasm, Residual (2)  ·  Central Nervous System Neoplasms (1)

Broader conditions

Hematologic Diseases (38)  ·  Hemic and Lymphatic Diseases (38)  ·  Immune System Diseases (38)  ·  Immunoproliferative Disorders (38)  ·  Lymphatic Diseases (38)  ·  Lymphoproliferative Disorders (38)  ·  Neoplasms (38)  ·  Neoplasms by Histologic Type (38)  ·  Leukemia, Lymphoid (37)  ·  Leukemia (29)  ·  Lymphoma, Non-Hodgkin (18)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (18)  ·  DNA Virus Infections (16)  ·  Epstein-Barr Virus Infections (16)  ·  Herpesviridae Infections (16)

Interventions

Cyclophosphamide (15)  ·  Dexamethasone (13)  ·  Cytarabine (11)  ·  Vincristine (11)  ·  Methotrexate (9)  ·  Doxorubicin (7)  ·  Inotuzumab Ozogamicin (7)  ·  blinatumomab (7)  ·  venetoclax (7)  ·  Prednisone (6)  ·  merphos (6)  ·  pegaspargase (6)  ·  Calcium Dobesilate (5)  ·  Mercaptopurine (5)  ·  Specimen Handling (5)

Sponsors

Princess Maxima Center for Pediatric Oncology (5)  ·  Children's Oncology Group (3)  ·  First Affiliated Hospital of Zhejiang University (3)  ·  University of Washington (3)  ·  Medical College of Wisconsin (2)  ·  Seagen Inc. (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Ankara Children's Health and Diseases Hematology and Oncology Training and Research Hospital (1)  ·  Asan Medical Center (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  City of Hope Medical Center (1)  ·  ECOG-ACRIN Cancer Research Group (1)  ·  Fate Therapeutics (1)  ·  Institut de Cancérologie de la Loire (1)  ·  Institute of Hematology & Blood Diseases Hospital, China (1)

Countries

United States (19)  ·  China (6)  ·  Puerto Rico (6)  ·  France (5)  ·  Australia (4)  ·  Ireland (4)  ·  Netherlands (4)  ·  Spain (4)  ·  Austria (3)  ·  Belgium (3)  ·  Canada (3)  ·  Denmark (3)  ·  Finland (3)  ·  Germany (3)  ·  Israel (3)

Top investigators

Michel Zwaan, Prof. Dr. (3)  ·  Andrej Lissat, MD PhD (2)  ·  Mary Horowitz, MD, MS (2)  ·  Paco Bautista, MD PhD (2)  ·  Ryan Cassaday (2)  ·  Ana Kostic, MD (1)  ·  Andrej Lissat, MD, PhD (1)  ·  Anna Halpern, MD (1)  ·  Anne L Angiolillo (1)  ·  Chantal Le Guellec, PharmD, PhD (1)  ·  Dae-Young Kim, MD, PhD (1)  ·  Elias Jabbour (1)  ·  Emmanuelle Tavernier, MD (1)  ·  Eric Feldman, MD (1)

Results publications

PMID 41671463, PMID 35622074, PMID 21527516, PMID 24862638, PMID 23233571, PMID 24433481, PMID 31969338, PMID 33191168, PMID 33411585, PMID 33844429, PMID 35007127, PMID 36279879, PMID 37890117, PMID 38722664, PMID 39121442, PMID 39415930, PMID 39651791, PMID 39882642, PMID 40315406, PMID 42154791

NIH funding

U10CA180886 (4), U01HL069294 (2), U24CA076518 (2), 2009 (1), 2018 (1), 2025 (1), P30CA015704 (1), P30CA033572 (1), U10CA098543 (1), U10CA180820 (1), U10CA180821 (1)